Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX AvKARE — Intellectual property legal development expenses

Other segment segments

Affordable Medicines
$2M+1.2%

Similar metrics at other companies

EyePoint, Inc. logo
EYPTIntellectual Property Expense
$224.5K-34.0%
EyePoint, Inc. logo
EYPTIntellectual Property Expense
$224.5K-34.0%
Adeia logo
ADEAIntellectual Property Licensing — Legal Fees
$5.33M-25.6%
International Business Machines logo
IBMIntellectual Property and Custom Development Income
$172M-32.0%
Clarivate logo
CLVTIntellectual Property Group — Technology Expenses
$12.5M-0.8%
Clarivate logo
CLVTIntellectual Property Group — People-Related Expenses
$69.4M-5.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept amrx:IntellectualPropertyLegalDevelopmentExpenses.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Three Months Ended June 30, 2026Affordable Medicines (1)SpecialtyAv KARECorporateand OtherTotal Company
Gross profit207,229101,03026,249334,508
Selling, general and administrative42,36740,09516,91349,347148,722
Research and development33,0235,99439,017
Intellectual property legal development expenses2,002852,087
Acquisition costs7,6007,600
Restructuring and other charges554554
Charges related to legal matters, net8,0578,057
Other operating income(1,298)(1,298)

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s avkare — intellectual property legal development expenses?
Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — intellectual property legal development expenses of $0 in Q2 2026.
What does avkare — intellectual property legal development expenses mean?
Reflects costs associated with protecting, maintaining, and defending the intellectual property rights of the AvKARE segment's product portfolio. These expenses are critical for sustaining competitive advantages and preventing market entry by generic or biosimilar competitors.

Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — intellectual property legal development expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude